@article{dc95d317583d414983486c7e4699ee0a,
title = "Metagenomics and chemotherapy-induced nausea: A roadmap for future research",
abstract = "Uncontrolled chemotherapy-induced nausea and vomiting can reduce patients' quality of life and may result in premature discontinuation of chemotherapy. Although nausea and vomiting are commonly grouped together, research has shown that antiemetics are clinically effective against chemotherapy-induced vomiting (CIV) but less so against chemotherapy-induced nausea (CIN). Nausea remains a problem for up to 68% of patients who are prescribed guideline-consistent antiemetics. Despite the high prevalence of CIN, relatively little is known regarding its etiology independent of CIV. This review summarizes a metagenomics approach to the study and treatment of CIN with the goal of encouraging future research. Metagenomics focuses on genetic risk factors and encompasses both human (ie, host) and gut microbial genetic variation. Little work to date has focused on metagenomics as a putative biological mechanism of CIN. Metagenomics has the potential to be a powerful tool in advancing scientific understanding of CIN by identifying new biological pathways and intervention targets. The investigation of metagenomics in the context of well-established demographic, clinical, and patient-reported risk factors may help to identify patients at risk and facilitate the prevention and management of CIN.",
author = "Crowder, {Sylvia L.} and Hoogland, {Aasha I.} and Welniak, {Taylor L.} and LaFranchise, {Elizabeth A.} and Carpenter, {Kristen M.} and Daneng Li and Rotroff, {Daniel M.} and Arshiya Mariam and Pierce, {Christine M.} and Fischer, {Stacy M.} and Kinney, {Anita Y.} and {Dong-Binh Tran}, Thi and Farzaneh Rastegari and Berry, {Donna L.} and Martine Extermann and Kim, {Richard D.} and Tometich, {Danielle B.} and Figueiredo, {Jane C.} and Jameel Muzaffar and Shahla Bari and Kea Turner and Weinstock, {George M.} and Jim, {Heather S.L.}",
note = "Funding Information: Daniel M. Rotroff reports membership on the board of directors for Bluem, leadership roles in Interpares Biomedicine and Clarified Precision Medicine, and equity stakes in Interpares Biomedicine and Clarified Precision Medicine. Christine M. Pierce reports stock in and is a current employee of Merck Sharp & Dohme Corp. Martine Extermann has consulted for Alnylam and reports payments or honoraria from OncLive. Daneng Li reports grants from Brooklyn Immunotherapeutics and AstraZeneca as well as personal fees from Lexicon, Ipsen, Eisai, Exelixis, Advanced Accelerator Applications, Bayer, Genentech, Taiho, Coherus, Sun Pharma, and QED outside the submitted work. Heather S. L. Jim is a consultant to RedHill BioPharma, Janssen Scientific Affairs, and Merck and has received grant funding from Kite Pharma. Dr. Kinney has received grant funding fron Pfizer Global. The other authors made no disclosures. Funding Information: This study was funded by the National Cancer Institute (R01CA219389 [principal investigator Heather S. L. Jim], R01 NR018762 [principal investigators Jane C. Figueiredo and Heather S. L. Jim], and T32CA090314 [multiple principal investigators Thomas Brandon and Susan Vadaparampil]). Publisher Copyright: {\textcopyright} 2021 American Cancer Society",
year = "2022",
month = feb,
day = "1",
doi = "10.1002/cncr.33892",
language = "English (US)",
volume = "128",
pages = "461--470",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",
}